Teladoc (TDOC) Stock May Trade At A 44% Discount After Soft Q2 Results

Teladoc Health has seen its share price fall a long way over the past few years, and the market is now effectively asking whether the current US$6.28 level can be justified by the cash the business is expected to generate. With the stock still reacting to recent news, the key issue for you is whether the cash flow outlook lines up with what the market is paying today.

• The share price has declined about 95.5% over 5 years, which puts the focus squarely on whether the remaining equity value is supported by Teladoc Health's future cash flows.
• Recent revenue softness and weaker expectations have raised questions about how quickly Teladoc Health can convert its virtual care model into consistent cash generation that supports its current valuation.
• If you'd rather focus on sales, this one's for you. See what Teladoc Health's 0.5x P/S says about the price.

The issue now is whether Teladoc Health's current share price is aligned with its intrinsic value when you only look at the cash flows implied by the Discounted Cash Flow (DCF) estimate.

If Teladoc Health's share price reset has you reassessing where cash flow focused ideas might come from next, a good starting point is a curated list built around 29 high quality undervalued stocks.

Does Teladoc Health Look Undervalued on Cash Flow?

The Discounted Cash Flow model used here evaluates the cash Teladoc Health could return to shareholders over time and discounts those amounts back to today. In this framework, the business is viewed as a cash generator rather than only a revenue story.

Over the last twelve months Teladoc Health produced roughly $120.2 million in free cash flow, and the projections used in the model assume that these cash flows grow from this base rather than shrink. That reflects an expectation that the virtual care model will continue to fund the business without relying purely on outside capital.

Recent Q2 results showed revenue down 4% and softer guidance, which helps explain why the market is pricing the stock at $6.28, even though the Discounted Cash Flow projections put Teladoc Health's estimated intrinsic value substantially above the current share price. Find out what Teladoc Health could be worth using our Discounted Cash Flow (DCF) estimate.

The Teladoc Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Teladoc Health pick up where the valuation puzzle leaves off by spelling out which paths for growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price. Each narrative ties a fair value to a specific version of Teladoc Health's future, anchored in its potential catalysts and key risks, so you can track over time which storyline is actually unfolding.

Community views on Teladoc Health split into one group that sees a cash rich turnaround story and another that worries margin pressure and competition keep dragging on value.

Bull case: 58% undervalued

"Teladoc is a cash-generative healthcare utility with $750M+ in hard cash protecting the downside, $130M–$170M in annual free cash flow…"

Discover why this Narrative puts Teladoc Health at 58% undervalued.

Bear case: 14% overvalued

"Margin pressures are likely to intensify due to lower unit economics as BetterHelp's insurance-based mental health revenues scale, since insurance reimbursement yields significantly lower gross profits…"

Explore why this Narrative puts Teladoc Health at 14% overvalued.

Before focusing only on Teladoc Health's valuation, check what the risk checks are flagging

Valuation is only one piece of the Teladoc Health puzzle, and the research here has also highlighted specific risk checks that deserve your attention before you lean on the numbers. Take a closer look at 2 warning signs before settling on a valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com